Ascletis Pharma Inc. (HKG:1672)
13.12
+0.43 (3.39%)
Feb 3, 2026, 3:04 PM HKT
Ascletis Pharma Revenue
Ascletis Pharma had revenue of 1.08M CNY in the half year ending June 30, 2025, a decrease of -97.68%. This brings the company's revenue in the last twelve months to 2.36M, down -76.57% year-over-year. In the year 2024, Ascletis Pharma had annual revenue of 1.28M, down -97.73%.
Revenue (ttm)
2.36M CNY
Revenue Growth
-76.57%
P/S Ratio
4,834.58
Revenue / Employee
11.37K CNY
Employees
208
Market Cap
12.52B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28M | -55.31M | -97.73% |
| Dec 31, 2023 | 56.60M | 2.51M | 4.63% |
| Dec 31, 2022 | 54.09M | -22.79M | -29.64% |
| Dec 31, 2021 | 76.88M | 41.88M | 119.64% |
| Dec 31, 2020 | 35.00M | -138.44M | -79.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 3.44B |
| Shanghai Haohai Biological Technology | 2.74B |
| Keymed Biosciences | 955.73M |
| Everest Medicines | 932.82M |
| HBM Holdings | 908.35M |
| Alphamab Oncology | 861.24M |
| Ascentage Pharma Group International | 428.02M |
| Mirxes Holding Company | 166.32M |